Holding(s) in Company
01 Julho 2009 - 2:13PM
UK Regulatory
TIDMOMH
RNS Number : 9626U
Osmetech PLC
01 July 2009
1 July 2009
Disclosure of Significant Shareholdings
Osmetech PLC ("Osmetech" or "the Company") (AIM:OMH) announces that it was
notified between 25 June 2009 and 30 June 2009 of the following changes in
shareholdings of ordinary 0.1p shares pursuant to the placing announced on 25
June 2009 (the "June Placing"):
1. Efficacy Capital Limited ('Efficacy') purchased 7,617,307 shares in
the Company in the June Placing
increasing its total interest
in Osmetech to 307,200,049 shares representing 26.63% or the current
issued share capital. Efficacy's interest is held as follows:
+---------------------------------+---------------+----------------+
| Registered Owner | Number of | % of issued |
| | ordinary | share capital |
| | shares | |
+---------------------------------+---------------+----------------+
| Efficacy Biotech Master Fund | 304,230,049 | 26.37% |
+---------------------------------+---------------+----------------+
| FMG Special Opportunity Fund | 2,970,000 | 0.26% |
+---------------------------------+---------------+----------------+
| Total | 307,200,049 | 26.63% |
+---------------------------------+---------------+----------------+
2. Jeffrey Taylor purchased 7,617,307 shares in the Company in the June
Placing through Bankers
Union Trust. Jeffrey Taylor's total
interest in Osmetech shares is now 84,069,243 shares
representing 7.29% or the current issued share capital. Jeffrey Taylor's
interest is held as follows:
+----------------------------------+---------------+----------------+
| Registered Owner | Number of | % of issued |
| | ordinary | share capital |
| | shares | |
+----------------------------------+---------------+----------------+
| Crown Taylor Money Purchase | 64,951,936 | 5.63% |
| Pension Plan | | |
+----------------------------------+---------------+----------------+
| Bankers Union Trust | 19,117,307 | 1.66% |
+----------------------------------+---------------+----------------+
| Total | 84,069,243 | 7.29% |
+----------------------------------+---------------+----------------+
3. Gartmore Investment Limited has increased its shareholding in
Osmetech from
189,298,177 to 222,814,326 shares, representing
19.31% of the Company's issued share capital.
+------------+-------------+-------------+---------------+---------------+
| Fund | Number of | % of issued | UK Registered | Beneficial |
| Managing | ordinary | share | Owner | Owner |
| Co. | shares | capital | | |
+------------+-------------+-------------+---------------+---------------+
| Gartmore | 59,358,493 | 5.145% | HSBC Global | Gartmore Fund |
| Fund | | | Custody | Managers |
| Managers | | | Nominee UK | Limited A/C. |
| Limited | | | Ltd | Gartmore UK & |
| | | | | Irish Smaller |
| | | | | Companies |
+------------+-------------+-------------+---------------+---------------+
| Gartmore | 43,885,505 | 3.804% | Northtrust | Strathclyde |
| Investment | | | Nominees | Pension Fund |
| Limited | | | Limited | |
+------------+-------------+-------------+---------------+---------------+
| Gartmore | 103,090,283 | 8.936% | Vidacos | The Alphagen |
| Investment | | | Nominess Ltd | Volantis Fund |
| Limited | | | A/C 2303 | Limited |
+------------+-------------+-------------+---------------+---------------+
| Gartmore | 16,480,045 | 1.429% | Gartmore | Gartmore |
| Investment | | | Growth | Growth |
| Limited | | | Opportunities | Opportunities |
| | | | | PLC |
+------------+-------------+-------------+---------------+---------------+
4. Polar Capital Healthcare Opportunities Fund's has not purchased
additional shares in the Company
in the June Placing and its
total interest in Osmetech is 31,651,936, representing 2.74% of the
Company's issued share capital, which has been reduced as a result of the
additional placing shares.
The total number of issued ordinary 0.1p shares is 1,153,642,510. Osmetech does
not hold any ordinary shares in Treasury. Therefore, the total number of voting
rights in Osmetech is 1,153,642,510.
For further information:
+--------------------------------+-----------------------------------------------+
| Osmetech plc: | +44 (0) 20 7849 6027 |
+--------------------------------+-----------------------------------------------+
| James White, Chief Executive | |
+--------------------------------+-----------------------------------------------+
| David Sandilands, Finance | |
| Director | |
+--------------------------------+-----------------------------------------------+
| | |
+--------------------------------+-----------------------------------------------+
| Madano Partnership: | +44 (0) 207 593 4000 |
+--------------------------------+-----------------------------------------------+
| Mark Way | |
+--------------------------------+-----------------------------------------------+
| Graham Moonie | |
+--------------------------------+-----------------------------------------------+
| | |
+--------------------------------+-----------------------------------------------+
| Canaccord Adams Limited: | +44 (0) 20 7050 6500 |
+--------------------------------+-----------------------------------------------+
| Robert Finlay | |
+--------------------------------+-----------------------------------------------+
| Henry Fitzgerald-O'Connor | |
+--------------------------------+-----------------------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLSSUFWFSUSESW
Osmetech (LSE:OMH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Osmetech (LSE:OMH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
